2017
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis & Rheumatology 2017, 69: 1521-1537. PMID: 28585373, DOI: 10.1002/art.40137.Peer-Reviewed Original ResearchConceptsOral bisphosphonate treatmentGlucocorticoid-induced osteoporosisVitamin DGC treatmentAntifracture medicationsBisphosphonate treatmentFracture riskGC usersHigh-dose GC treatmentLong-term glucocorticoid treatmentLong-term GC treatmentSpecial populationsHarms of interventionsHigh fracture riskLower fracture riskQuality of evidenceGeneral adult populationBisphosphonate regimenGIOP preventionOral bisphosphonatesOsteoporosis medicationsRheumatology guidelinesDenosumab treatmentLifestyle modificationRecommendations Assessment
1998
Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty.
Buckley L, Marquez M, Hudson J, Downs R, Vacek P, Small R, Poses R. Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. The Journal Of Rheumatology 1998, 25: 2195-202. PMID: 9818664.Peer-Reviewed Original ResearchConceptsEstrogen replacement therapyCorticosteroid treatmentPhysician judgmentCorticosteroid usePhysician specialtySide effectsPostmenopausal patientsVitamin DBone lossReplacement therapyCorticosteroid-induced osteoporosisImportance of osteoporosisVitamin D supplementationMajority of patientsRisk of osteoporosisPrimary care physiciansSignificant side effectsHypothetical clinical scenariosImportance of corticosteroidsEfficacy of treatmentD supplementationPostmenopausal womenPremenopausal womenPhysician assessmentCare physicians